news
Promising Phase 3 results for E/C/F/TAF regimen presented at IAS
22 July 2015 | By Victoria White
Detailed 48-week data from a Phase 3 study evaluating E/C/F/TAF regimen in patients with HIV-1 was presented at the 8th IAS Conference...
List view / Grid view
Gilead Sciences
news
EC approves Evotaz for the treatment of HIV-1 infection in adults
16 July 2015 | By Victoria White
The EC has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults...
news
Gilead submits NDA for single tablet regimen for HIV containing rilpivirine, emtricitabine and tenofovir alafenamide (R/F/TAF)
2 July 2015 | By Victoria White
Gilead Sciences has submitted a NDA to the FDA for an investigational, once-daily single tablet regimen for the treatment of HIV-1 infection...
news
NICE seeks more information on idelalisib from Gilead
18 June 2015 | By Victoria White
NICE has opened a consultation on preliminary draft guidance for the drug idelalisib (Zydelig) for adults with chronic lymphocytic leukaemia...
news
Idelalisib in combination with ofatumumab improves progression-free survival in previously-treated patients with chronic lymphocytic leukaemia
1 June 2015 | By Victoria White
Results from a study of idelalisib in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukaemia have been announced...
news
EMA validates Marketing Application for fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) for HIV treatment
29 May 2015 | By Victoria White
Gilead’s MAA for a fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) has been fully validated and is now under evaluation by the EMA..
news
Top-line results announced for Phase 2 study of GS-4774 in patients with chronic hepatitis B
28 May 2015 | By Victoria White
Top line results have been announced from the GS-4774 Phase 2 study in patients with HBV on long term viral suppression with an oral antiviral treatment...
news
Harvoni and Sovaldi demonstrate efficacy among chronic hepatitis C patients with advanced liver disease
23 April 2015 | By Victoria White
Results announced from several Phase 2 clinical studies evaluating uses of Harvoni and other Sovaldi-based regimens for the treatment of HCV infection...
news
Gilead submits New Drug Application for F/TAF for the treatment of patients with HIV
8 April 2015 | By Victoria White
Gilead has submitted a NDA to the FDA for an investigational fixed-dose combination of F/TAF for the treatment of HIV-1 infection...
news
Gilead receives approval from the Scottish Medicines Consortium for use of zydelig® (idelalisib) for the treatment of chronic lymphocytic leukaemia
9 March 2015 | By Gilead Sciences
New oral treatment for Chronic Lymphocytic Leukaemia now approved for use within NHS Scotland...
news
Gilead announces SVR12 rates from Phase 3 study evaluating Harvoni® for the treatment of chronic hepatitis C in patients co-infected with HIV
27 February 2015 | By Gilead Sciences
96 percent SVR12 rate for hepatitis C genotypes 1 and 4 among HIV-infected patients on antiretroviral therapy...
news
Gilead announces Phase 3 results for investigational once-daily single tablet HIV regimen containing tenofovir alafenamide (TAF)
27 February 2015 | By Gilead Sciences
First TAF-based regimen found to be non-inferior with improved renal and bone parameters compared to stribild®...
news
Hepatitis C: Doctors of the World opposes patent for sofosbuvir
10 February 2015 | By Doctors of the World
Doctors of the World - Médecins du Monde is today filing its opposition to the patent granted for sofosbuvir (Sovaldi) with the European Patent Office...
news
Gielad presents follow-up data from idelalisib (zydelig®) registrational studies in patients with chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma
11 December 2014 | By Gilead Sciences
Results describing long-term safety and disease control presented at the 56th American Society of Hematology Annual Meeting...
news
Gilead announces Harvoni® (ledipasvir/sofosbuvir) study results in chronic hepatitis C patients with advanced liver disease and those who failed prior treatment
13 November 2014 | By Gilead Sciences
High cure rates in nearly 800 Hepatitis C Virus (HCV patients with advanced liver disease)...
